Advertisement
Advertisement
ENGN
enGene Therapeutics Inc. Common Stock
1.79
USDSponsored
+0.03
+1.70%
Jul 31, 15:56 UTC -4
Closed
After-Market
1.79
0.00
+0.28%
ENGN Earnings Reports
Positive Surprise Ratio
ENGN beat 4 of 9 last estimates.
44%
Next Report
Date of Next Report
Sep 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.43
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-23.21%
enGene Therapeutics Inc. Common Stock earnings per share and revenue
On Jun 15, 2026, ENGN reported earnings of -0.43 USD per share (EPS) for Q2 26, beating the estimate of -0.47 USD, resulting in a 10.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.43 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
Myriad Genetics Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.25
Surprise
-323.73%
Crescent Biopharma, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.74
Surprise
+8.74%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.20%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.46
Actual
$14.29
Surprise
+36.51%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.42
Actual
$0.92
Surprise
+116.37%
FAQ
What were enGene Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, enGene Therapeutics Inc. Common Stock reported EPS of -$0.43, beating estimates by 10.32%, and revenue of $0.00, 0% as expectations.
How did the market react to enGene Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 9.26%, changed from $1.62 before the earnings release to $1.77 the day after.
When is enGene Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Sep 09, 2026.
What are the forecasts for enGene Therapeutics Inc. Common Stock's next earnings report?
Based on 11
analysts, enGene Therapeutics Inc. Common Stock is expected to report EPS of -$0.43 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement